Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous

Erin, look, it's a real pleasure to be here. You know, thank you for the engagement, for the reconnection, for the opportunity to be part of this really sophisticated and well-versed podcast series in cell and gene therapy, something that I'm really passionate about and I know that you are as well.

Yeah, it's a great question and I think it's absolutely pivotal, Erin. We always have to remember that the patient has to be at the epicenter of everything we do and everything that we say. And that's certainly been a very clear message from me as I sort of think about my personal experiences in cell and gene therapy, starting my career in BMT and stem cell transplantation, taking that experience and then moving into biotech and biopharma and really developing these highly complex therapeutics. I think when we zoom out and we sort of just almost kind of examine the entire cell therapy pathway from patient diagnosis right through to long-term follow-up, I think to answer your question, the areas of greatest friction are rarely confined to a single step. I think they occur in transitions. As I think about the patient journey, the referral stage, the manufacturing interval when we think about autologous CAR-T for example, the post-infusion monitoring phase. So I think if we kind of segment it, the first friction point in my mind is access and referral. So many patients are eligible for advanced therapies, but these patients may not be treated at major academic centers. They may be managed in community settings where awareness of ongoing trials may be limited, for example. So I think we need to focus on awareness and education. By the time a referral is made, when we think about some of these disease entities, the disease may have progressed, eligibility criteria may have narrowed, or even the patient's clinical status may have changed. So I think the delay is not just an operational one. It's quite emotional for the patient.

And patients and families often describe this early part of this referral process as being very opaque and slow, particularly when for some patients time is critical, such as in the relapsed hematological malignancy setting. So I think that's one thought. I think the second and perhaps most distinctive friction point in cell therapy is the vein-to-vein interval, particularly again in the more complex scenarios such as autologous treatments, from apheresis to manufacturing to release testing. And this period can feel like a prolonged holding period for patients. Again, there's a lot of anxiety. The patient is in this holding pattern almost. So I think whilst these processes are scientifically and regulatory essential, for patients they represent a degree of uncertainty. They're waiting while the disease biology continues to evolve, because cancer for example is very complex and can be very transformative in terms of that evolution of the disease. So I think reducing that vein-to-vein time, improving predictability of things like manufacturing slots, and providing really transparent communication checkpoints during production, for example, could dramatically improve patient confidence and reduce anxiety. Again, really thinking about how do we put ourselves as drug developers in the shoes of the patient and really take that journey.

And then the third friction point in my mind is long-term follow-up. So we know that gene-modified therapies require extended monitoring, often spanning many years. Again, for patients who may feel clinically well after an infusion, repeated visits to specialized centers can feel burdensome. If we think about travel and time off work, caregiver logistics, depending on the scenario, cumulative fatigue is often underappreciated. So again, this is where we need to think very creatively in terms of things like hybrid monitoring models, if a patient's been in a clinical trial for example, or maybe integrating local laboratories. There's a focus on being much more innovative in terms of digital solutions. So using telemedicine, remote data capture. I think all of these offer a very meaningful opportunity to really simplify the patient journey somewhat without compromising regulatory rigor, because this is a highly regulated environment.

So ultimately, I think simplification is most needed at these transition points for the patient, particularly where operational complexity directly intersects with that patient vulnerability. And that's what we need to really pay attention to.

Yeah, you know, again, I think it's a really great question and very pertinent. I think these upstream decisions in cell therapy development are in effect somewhat architectural. This is the framework, the practical framework or the infrastructure that we build around the patient or around the patient journey. So once the patient is enrolled, it's often too late to correct structural burdens embedded in the protocol or again around that framework that we're building around the patient and the patient journey. Eligibility criteria is a prime example. So whilst we can be very scientifically justified, they can be overly restrictive, and the criteria potentially can exclude patients who are clinically stable enough to benefit. Moreover, when we think about that overarching criteria, complex screening algorithms requiring multiple imaging studies or repeated biopsies or extensive lab panels. Again, let's think about putting ourselves in the shoes of the patient. This adds procedural burden, and this is before a patient even begins therapy. So I think each additional requirement increases our risk of attrition. But for the patient, this is also a psychological fatigue.

When we talk about manufacturing and manufacturing strategy, also profoundly shapes the patient experience. So as we'd mentioned earlier in the autologous model, centralized manufacturing may provide quality consistency, but it can limit geographic flexibility. So if we bring that back to the site and the patient experience, we think about slot allocation systems that are not synchronized with disease progression or the dynamics, and this can create both ethical and logistical dilemmas. So again, these are intricacies that need to be highly conjugated to that patient journey. But conversely, a decentralized or regional manufacturing hub may improve responsiveness, but maybe introduce additional coordination challenges. So these are strategic decisions. They're not merely technical, and I think they determine how long a patient waits, how far they travel, and how predictable their treatment timeline actually feels. And we mentioned earlier about the anxiety that the patient feels during these windows of time.

I think the other thing I would mention is, very similarly, cold chain design and supply chain integration again influence reliability. For example, a cancelled infusion due to a courier delay or documentation discrepancy, it's not just simply an operational event. It's a deeply destabilizing moment for a patient who is prepared emotionally and physically for the treatment. So in many respects, operational design is patient-centered care, but with some degree of nuance. And when we thoughtfully align upstream decisions, they can create a seamless journey. But when it's misaligned, they amplify friction at precisely the moments when patients are most vulnerable. And I think that's why coming together as key stakeholders within the ecosystem to really ensure that we are focusing on the patient journey and influencing it as positively as possible, that is what's going to help us really scale and bring these transformational therapies to patients with real benefit.

Yeah, you know, again, it kind of reminds me of my personal experiences when it comes to designing trials, designing that framework as I'd mentioned, the infrastructure that we need to build around the patient. I mean, cell and gene therapies are among the most scientifically complex interventions in modern medicine. I think the treatment effects are irrefutable. Yet patients must understand and consent to these therapies, and that usually occurs within a relatively short window for some of the reasons that I previously shared. Again, I cast my mind back to my time in BMT and stem cell transplantation, the very early days of immunotherapy as we know it today. So improving clarity and trust begins with rethinking in some ways how information is delivered. I think certainly in my experience, consent documents are often very dense, very technical, they have a regulatory tone, and whilst completeness is essential, comprehension is equally critical. So it's finding that balance. I think a layered consent approach, combining maybe written documentation with visual summaries, for example, or structured discussion sessions and opportunities for repeated questioning, that can significantly enhance understanding. And patients should not feel rushed into consent; rather, they should feel progressively informed.

Being a chairman of a patient advocacy group in the rare disease space, for me personally, it's about how do we develop those tools and those opportunities to engage and to help amplify the patient voice. And I think even having dedicated patient navigators could be another really transformative intervention, a single point of contact who understands the protocol, who coordinates appointments and facilitates travel support, answers logistical questions, and reduces fragmentation in that part of the process, which is really critical for the patient. And in complex therapies that involve apheresis or conditioning regimens or inpatient monitoring, long-term follow-up, this continuative communication is foundational to building the trust of patients.

So in some ways, speed is also crucial. As we'd mentioned before, delays in screening approval or even things that we take for granted, insurance verification or scheduling, that creates distress and anxiety. So having clear milestone-based timelines, even if they include some level of contingency because unfortunately things do go wrong, that helps to manage patients' planning and their expectations. So transparency about what is known, what remains uncertain, and what may change builds credibility with the patient. And ultimately, I think we focus on this because it's so imperative, but ultimately trust is established not solely through scientific excellence but through consistency, clarity, and responsiveness, certainly in my personal experiences.